Summary. In order to evaluate the role of glucagon in blood glucose homeostasis in liver cirrhosis, ten normal subjects and ten cirrhotic patients were infused with somatostatin (500 ~g/h for 5 h) with and without glucagon (3 mg/kg/h) administration. Somatostatin infusion brought about a fall in plasma glucose both in normal (37%) and cirrhotic (41%) subjects in the first 90 minutes. In normal subjects, this was followed by a rise in plasma glucose (147 + 2 mg/dl at 5 h), while in cirrhotics no rise in plasma glucose was observed (50 + 1 mg/dl at 5 h). Plasma insulin and glucagon levels were suppressed in both normal and cirrhotic subjects. Addition of glucagon to the somatostatin infusion caused a two fold rise in plasma glucose level to 183 + 12 mg/dl at 4 h in normal subjects; a much smaller increase was found in the cirrhotic group (105 + 3 mg/dl at 4 h). When the infusion was stopped, plasma glucose fell both in normal and cirrhotic subjects (102 _ 14 and 87 _+ 2 mg/dl at 6h respectively). Subsequently, hyperglucagonaemia recurred in the cirrhotic patients (319 _ 31 pg/ml). A rebound of plasma insulin was observed in normal subjects (47 + 8 ~tU/ml) which did not occur in the cirrhotics (16 + 2 ~tU/ml). Thus when both insulin and glucagon were suppressed by somatostatin infusion, euglycaemia occurred in cirrhotic subjects only when glucagon concentration was restored exogenously. We conclude that glucagon is important in glucose homeostasis in patients with liver cirrhosis.
The hypothesis that pancreatic glucagon plays an important role in glucose homeostasis has been supported by studies with infusion of somatostatin [2, 7, 9, 15, 25] , a powerful inhibitor of both insulin and glucagon secretion [1, 2, 13, 17] .
Hyperglucagonaemia is known to be present in liver cirrhosis [11, 16, 18, 20, 22] ; the effect and importance of this with respect to metabolic regulation is as yet not fully understood.
The present investigation was undertaken in order to evaluate the contribution of glucagon to glucose homeostasis in cirrhotic patients by studying plasma glucose changes during prolonged somatostatin infusion with and without administration of glucagon.
Material and Methods
Two groups of subjects were studied, a control group of ten healthy male volunteers aged 28-36, whose body weights were within 15 per cent of the ideal value (Metropolitan Life Insurance Tables, 1959) and a group of ten male non diabetic, non ascitic cirrhotic patients aged 39-49 whose body weights, ranging from 53 to 68 kg (average 60 _+ 7 kg), 96 _+ 2% of ideal body weight. The diagnosis of liver cirrhosis was confirmed by peritoneoscopy and liver biopsy in every case. Characteristics of cirrhotic subjects at selection are shown in Table 1 .
All subjects were informed of the nature, purpose and possible risks of the study and had given their consent to participate.
For at least one week before the test, the subjects were fed a daily diet of about 3000 Calories with at least 280 g of carbohydrate. All tests were performed after an overnight fast. Catheters were introduced into the antecubital veins of both arms, one for drawing blood and the other for the infusion of somatostatin, saline (0.154 mol/1) or glucagon. After baseline blood specimens had been obtained over a 60 min period 250 p.g of sterile synthetic pyrogen-free cyclic somatostatin was injected; somatostatin infusion was then continued at on hourly rate of 500 ~tg for 5 h. In addition, from the second to the fourth hour, all subjects were infused with saline (0.154 mol/1) or glucagon (3 ng/kg/rnin) which yielded plasma glucagon levels of approximately 300-350 pg/ml. Blood specimens were drawn at 15-rain intervals for the following 5 h. Heparinized blood specimens for insulin assay were centrifuged at 4 ~ and subsequently frozen at -20 ~ until assay; for glucagon assay, 4 ml of blood were placed into chilled tubes containing 0.2 ml of disodium edetate solution (1.2 mg/ml blood); 0012-186X/80/0018/0187/$01.00 after centrifugation, the plasma was separated and frozen until assay. Plasma glucose was determined by the glucose oxidase method in a Beckman analyzer; plasma insulin (IRI) was estimated radioimmunologically [12] ; glucagon was measured radioimmunologically with Unger's 30 K antiserum [24] .
Results are presented as means + SEM. Student's t test for unpaired data was employed for statistical analysis.
Results

Figure i
shows the results obtained with somatostatin and glucagon infusion in normal and cirrhotic subjects.
Fasting plasma glucose levels were similar in both groups (Table 2 ). In normal subjects after 90 minutes of somatostatin infusion plasma glucose had fallen by 37% to 55 + 3 mg/dl; the level then rose again reaching 147 +_ 2 mg/dl at 5 hours. When somatostatin was stopped, plasma glucose returned to normal.
Cirrhotic subjects showed a similar fall in plasma glucose during the first 90 minutes (50 + 3 mg/dl) but thereafter plasma glucose levels remained low, values differing significantly from those observed in normal subjects (Table 2 ). Once the infusion was stopped, plasma glucose concentration returned to normal.
Basal plasma insulin values (Table 3) did not differ significantly between normal and cirrhotic subjects; during somatostatin infusion, insulin levels were markedly suppressed. Basal plasma glucagon values (Table 4) were significantly higher in cirrhotic patients as compared to normal controls (351 + 15 as against 99 + 2 pg/ml; P < 0.001). After somatostatin infusion, glucagon levels were markedly suppressed and the difference between the two groups disappeared.
IV glucagon infusion (3 ng/kg/min) 2 hours after the beginning of somatostatin infusion brought the glucagon levels to 293 + 11 pg/ml in normals and 368 + 6 pg/ml in cirrhotics respectively within 90 minutes. At the same time, a gradual rise in plasma glucose was observed which after 120 minutes of glucagon infusion reached 183 + 12 mg/dl in normals and 105 _+ 3 mg/dl in cirrhotics (P < 0.001). When glucagon was stopped, plasma glucose values in cirrhotics dropped to a level significantly lower than that of normal subjects (83 _+ 2 compared to 146 + 15 mg/dl; P < 0.001).
After somatostatin infusion was stopped, a fall in plasma glucose was observed (120 + 14 mg/dl); in the cirrhotic patients, basal plasma glucose values were reached in about an hour (87 + 2 mg/dl). Plasma glucagon returned to basal values rapidly both in normals and cirrhotics; this, in the latter led again to a condition of hyperglucagonaemia (320 + 32 pg/ml). In normal subjects, an insulin rebound was observed at 6 hours (47 + 8 ~U/ml) contrary to what was found in cirrhosis (16 _+ 2 ~tU/ml).
Discussion
The group of control subjects had a different mean age than the cirrhotics but that did not seem to influence our results significantly. Berger et al. [4] stated that plasma insulin levels did not change appreciably with age. Plasma glucagon levels change slightly from 20 to 40 years of age and glucose shows variations of 1-2 mg/dl per decade.
It has been clearly established that glucagon plays a physiological role in maintaining fasting euglycaemia in man [2, 5, 6, 9, 14, 15, 23] . Somatostatin infusion initially lowers basal plasma glucose in normal and diabetic man and it is suggested that this hypoglycaemic effect is a consequence of glucagon suppression [8] [9] [10] 17 ]. This fall is a reflection of decreased splanchnic glucose output [3, 5, 6 ] mostly due to a decline in glycogenolysis [25] . Somatostatin-induced hypoglucagonaemia elicited the same effects in patients with cirrhosis, and presumably glucagon plays a similar role in fasting blood glucose homeostasis. In our studies, glycaemia fell by 37% in normals and by 41% in cirrhotics during the first 90 minutes of somatostatin infusion.
When somatostatin and saline infusion was continued beyond two hours in normal subjects, plasma glucose increased to hyperglycaemic values; when the infusion was interrupted, blood glucose returned to basal values. Somatostatin-induced hyperglycaemia is the result of decreased glucose utilization and return to normal [7] or even an increase [21] in hepatic glucose production. In cirrhotic patients we did not observe a rise in plasma glucose after the first 2 hours of somatostatin and saline infusion. This different plasma glucose pattern of cirrhotics, as compared to normal subjects, may be accounted for by the different concentration of metabolic substrates in liver tissue. In cirrhosis, glucose output from the liver is likely to depend on gluconeogenesis since the hepatic glycogen stores are virtually exhausted [20] .
The addition of glucagon to somatostatin infusion in normal subjects enhanced the hyperglycaemic effect of prolonged somatostatin infusion producing a prompt twofold rise in plasma glucose due to increased glucose production [21] . In cirrhotics, the simultaneous infusion of somatostatin and glucagon 
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Our findings in cirrhotics submitted to prolonged somatostatin infusion show that when both insulin and glucagon were suppressed to unmeasurable concentrations, euglycaemia occurred only when the glucagon concentration was restored either exogenously or endogenously after 5 hours of somatostatin infusion.
Cirrhotic patients appear to lack the non-glucagon-dependent mechanisms of blood glucose control. In fact, the infusion of somatostatin alone did not bring about the rise in blood glucose observed in normal subjects, whereas the subsequent infusion of somatostatin and glucagon together had a hyperglycaemic action, albeit to a lesser extent than in norreals. Thus, hyperglucagonaemia appears to be an active mechanism for the maintenance of blood glucose levels in cirrhosis.
